Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value
Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value
复制标题
前列腺癌患者血清中miR-494表达升高及其潜在诊断价值
DOI：
10.7754/clin.lab.2019.190422
复制
发表时间：
2019-01-01
影响因子：
0.7
通讯作者：
Peng, Ji-Hong
中科院分区：
文献类型：
--
作者：
Cai, Bin;Peng, Ji-Hong
背景资料：前列腺癌是一种常见的男性恶性肿瘤，预后差，寻找早期诊断前列腺癌的分子诊断标志物是当务之急。目的：探讨血清miR-494表达水平对前列腺癌的诊断价值。方法：选择90例前列腺癌患者和90例良性前列腺增生患者作为研究对象，90例健康志愿者作为对照组。收集患者血清，采用RT-PCR方法检测miR-494的表达水平，分析miR-494的表达与患者临床特征的关系。分析miR-494表达与Gleason评分及血清前列腺特异性抗原（PSA）水平的相关性。结果：miR-494在前列腺增生组较对照组明显升高，且在前列腺癌组中的表达水平明显高于前列腺增生组。前列腺癌患者中miR-494的水平与肿瘤大小和肿瘤分期呈正相关。此外，前列腺癌患者miR-494水平与Gleason评分（r = 0.3371，p = 0.0012）和血清PSA水平（r = 0.3485，p = 0.0008）呈正相关。miR-494的AUC为0.8090（95%可信区间0.7343 ~ 0.8837），提示miR-494是诊断前列腺癌的敏感生物标志物。结论：miR-494在前列腺癌患者血清中表达上调，循环miR-494可作为前列腺癌早期诊断的生物标志物。
Background: Prostate cancer is a common male cancer with poor prognosis, and to find molecular diagnostic markers for the early diagnosis of prostate cancer is urgently needed. The aim of this study is to investigate the diagnostic value of serum expression level of miR-494 for prostate cancer.Methods: Ninety patients with prostate cancer and 90 patients with benign prostatic hyperplasia were enrolled in this study, and 90 healthy volunteers served as the control group. The serum of the participants was collected, and the expression level of miR-494 was measured by RT-PCR Then the relationship between the expression of miR-494 and the clinical characteristics of the patients was analyzed. Moreover, the correlation between the expression of miR-494 and the Gleason score as well as serum level of prostate specific antigen (PSA) were analyzed. Finally, the diagnostic value of miR-494 for the early diagnosis of prostate cancer was analyzed by ROC curve.Results: miR-494 was significantly increased in the prostatic hyperplasia group compared with the control group, and the level of miR-494 in the prostate cancer group was significantly higher than that in the prostatic hyperplasia group. The level of miR-494 in patients with prostate cancer was positively correlated with tumor size and tumor stage. Moreover, the level of miR-494 was positively correlated with the Gleason score (r = 0.3371, p = 0.0012) and serum level of PSA (r = 0.3485, p = 0.0008) in patients with prostate cancer. Finally, AUC of miR-494 was 0.8090 (95% confidence interval 0.7343 to 0.8837), suggesting that miR-494 is a sensitive biomarker for the diagnosis of prostate cancer.Conclusions: miR-494 was upregulated in the serum of the patients with prostate cancer and circulating miR-494 can be used as a biomarker for the early diagnosis of prostate cancer.